Atlas Trials

Mural Oncology, Inc

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Mural Oncology, Inc

RecordFirmDate
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (NCT05092360)Mural Oncology, Inc2022-01-10
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 (NCT04830124)Mural Oncology, Inc2021-09-27
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (NCT04592653)Mural Oncology, Inc2020-09-30
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer (NCT04144517)Mural Oncology, Inc2020-02-05
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) (NCT03861793)Mural Oncology, Inc2019-02-26

Track Mural Oncology, Inc automatically

Every clearance here is in the API, with alerts when new ones post.